Spexis announces promising pre-clinical data with
Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL,...
Source: globenewswire.com
Stay updated with breaking news from Spexi Macrocycle Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL,...
Spexis AG / Key word(s): Research Update/Study resultsSpexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas 13.12.2022 / 07:30 CET/CESTAllschwil, Switzerland, December 13, 2022 Spexis announces promising pre-clinical dat...